Exon 5 of the p53 gene is a target for deletions in ovarian cancer

Clinical Chemistry

Volumn 44, Issue 1, 1998, Pages 72-77

  Angelopoulou, Katerina ^a,b   Levesque, Michael A ^a,b   Katsaros, Dionyssios ^c   Shipman, Rob ^d   Diamandis, Eleftherios P ^a,b,e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TURIN   (Italy)

^d Visible Genetics Inc   (Canada)

^e MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BINDING SITE; CHROMOSOME 17; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DUPLICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; POINT MUTATION; PREVALENCE; TUMOR SUPPRESSOR GENE;

EID: 0031962692     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.1.72     Document Type: Article

References (25)

1. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet 1992;1:45-9.
2. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW. Definition of a consensus binding site for p53. Mol Cell Biol 1992;12:2866-71.
3. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-30.
4. Unger T, Nau MM, Segal S, Minna JD. p53, a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 1992;11:1383-90.
5. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
6. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54: 1169-74.
7. Nelson WG, Kastan MB. The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994;14:1815-23.
8. Lane DP. A death in the life of p53. Nature 1993;362:786-7.
9. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
10. Caron de Fromental Soussi T. Tp53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom Cancer 1992;4:1-15.
11. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
12. Jego N, Thomas G, Hamelin R. Short direct repeats flanking deletions, and duplicating insertions in the p53 gene in human cancers. Oncogene 1993;8:209-13.
13. Greenblatt MS, Grollman AP, Harris CC. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 1996;56:2130-6.
14. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991;6: 1685-90.
15. Millner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993;53:2128-32.
16. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-6.
17. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90:4961-5.
18. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutations and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994;83:118-24.
19. Skilling JS, Sood A, Niemann T, Lager DJ, Buller RE. An abundance of p53 null mutations in ovarian carcinoma. Oncogene 1996;13: 117-23.
20. Angelopoulou K, Diamandis EP. Identification of deletions and insertions in the p53 gene using multiplex PCR and high resolution fragment analysis: Application to breast and ovarian tumors. J Clin Lab Anal (in press).
21. Ausubel FM, et al., eds. Current protocols in molecular biology. New York: John Wiley and Sons, 1995:2.2.1-2.2.2.
22. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
23. Runnebaum IR, Tong XW, Moebus V, Heilmann V, Kieback DG, Kreienberg R. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet 1994;93:620-4.
24. Goh HS, Yao J, Smith DR. p53 point mutations and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.
25. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 1993;8: 1501-9.